Bezuclastinib shows promise in treating nonadvanced systemic mastocytosis
A 100 mg dose reduced mast cell burden, alleviated debilitating symptoms and improved quality of life compared to placebo.
A 100 mg dose reduced mast cell burden, alleviated debilitating symptoms and improved quality of life compared to placebo.
More than half of patients with indolent systemic mastocytosis reported mild or worse quality of life issues.
Mastocytosis increased the risk of venom-induced anaphylaxis, but food and drug allergies were often overreported.
Intranasal epinephrine powder’s rapid absorption makes it a promising alternative to traditional epinephrine injections, a company said.
Vigilant monitoring of gastrointestinal health is crucial for patients with systemic mastocytosis to avoid complications, a new study finds.